Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 146683 | 3.825 |
09:34 ET | 59660 | 3.7959 |
09:36 ET | 52887 | 3.785 |
09:38 ET | 20058 | 3.795 |
09:39 ET | 32130 | 3.795 |
09:41 ET | 29335 | 3.79 |
09:43 ET | 50034 | 3.825 |
09:45 ET | 32631 | 3.82 |
09:48 ET | 16062 | 3.83 |
09:50 ET | 16877 | 3.835 |
09:52 ET | 27257 | 3.835 |
09:54 ET | 51869 | 3.84 |
09:56 ET | 20208 | 3.84 |
09:57 ET | 15836 | 3.85 |
09:59 ET | 27732 | 3.85 |
10:01 ET | 14174 | 3.875 |
10:03 ET | 14107 | 3.86 |
10:06 ET | 48641 | 3.87 |
10:08 ET | 56866 | 3.88 |
10:10 ET | 35263 | 3.885 |
10:12 ET | 15826 | 3.895 |
10:14 ET | 34393 | 3.895 |
10:15 ET | 34792 | 3.895 |
10:17 ET | 45100 | 3.91 |
10:19 ET | 69778 | 3.91 |
10:21 ET | 69932 | 3.91 |
10:24 ET | 114452 | 3.9 |
10:26 ET | 51011 | 3.91 |
10:28 ET | 104986 | 3.91 |
10:30 ET | 21408 | 3.91 |
10:32 ET | 105684 | 3.904 |
10:33 ET | 94067 | 3.905 |
10:35 ET | 8695 | 3.9 |
10:37 ET | 30382 | 3.915 |
10:39 ET | 10631 | 3.915 |
10:42 ET | 1300 | 3.915 |
10:44 ET | 35500 | 3.922 |
10:46 ET | 10721 | 3.9295 |
10:48 ET | 20749 | 3.94 |
10:50 ET | 374392 | 3.92 |
10:51 ET | 56472 | 3.9113 |
10:53 ET | 133621 | 3.9099 |
10:55 ET | 32703 | 3.91 |
10:57 ET | 9107 | 3.91 |
11:00 ET | 31576 | 3.89 |
11:02 ET | 57320 | 3.9 |
11:04 ET | 11850 | 3.895 |
11:06 ET | 1300 | 3.9 |
11:08 ET | 1550 | 3.9 |
11:09 ET | 9108 | 3.9 |
11:11 ET | 39620 | 3.91 |
11:13 ET | 2019 | 3.91 |
11:15 ET | 7150 | 3.907 |
11:18 ET | 5257 | 3.91 |
11:20 ET | 12453 | 3.92 |
11:22 ET | 2903 | 3.91 |
11:24 ET | 3106 | 3.915 |
11:26 ET | 66767 | 3.9188 |
11:27 ET | 60155 | 3.9317 |
11:29 ET | 22338 | 3.935 |
11:31 ET | 11659 | 3.9399 |
11:33 ET | 6609 | 3.94 |
11:36 ET | 8530 | 3.935 |
11:38 ET | 4764 | 3.935 |
11:40 ET | 18326 | 3.94 |
11:42 ET | 102971 | 3.96 |
11:44 ET | 114423 | 3.95 |
11:45 ET | 15957 | 3.95 |
11:47 ET | 59987 | 3.945 |
11:49 ET | 47092 | 3.945 |
11:51 ET | 25316 | 3.96 |
11:54 ET | 133886 | 3.93 |
11:56 ET | 37158 | 3.915 |
11:58 ET | 591 | 3.915 |
12:00 ET | 16757 | 3.915 |
12:02 ET | 9858 | 3.915 |
12:03 ET | 40740 | 3.92 |
12:05 ET | 4526 | 3.92 |
12:07 ET | 27163 | 3.91 |
12:09 ET | 8213 | 3.915 |
12:12 ET | 8121 | 3.92 |
12:14 ET | 20269 | 3.915 |
12:16 ET | 1323 | 3.91 |
12:18 ET | 8824 | 3.915 |
12:20 ET | 16312 | 3.915 |
12:21 ET | 5000 | 3.915 |
12:23 ET | 9320 | 3.93 |
12:25 ET | 33524 | 3.94 |
12:27 ET | 35957 | 3.95 |
12:30 ET | 18469 | 3.945 |
12:32 ET | 8089 | 3.945 |
12:34 ET | 2947 | 3.95 |
12:36 ET | 13634 | 3.945 |
12:38 ET | 27503 | 3.945 |
12:39 ET | 88905 | 3.94 |
12:41 ET | 34080 | 3.935 |
12:43 ET | 13670 | 3.94 |
12:45 ET | 10027 | 3.945 |
12:48 ET | 23973 | 3.935 |
12:50 ET | 4240 | 3.935 |
12:52 ET | 3000 | 3.93 |
12:54 ET | 45925 | 3.9212 |
12:56 ET | 33876 | 3.93 |
12:57 ET | 11940 | 3.9297 |
12:59 ET | 14088 | 3.93 |
01:01 ET | 7467 | 3.9201 |
01:03 ET | 2190 | 3.925 |
01:06 ET | 9522 | 3.93 |
01:08 ET | 104892 | 3.925 |
01:10 ET | 1055 | 3.925 |
01:12 ET | 1914 | 3.925 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.1B | -11.3x | --- |
Vera Therapeutics Inc | 2.1B | -19.5x | --- |
CG Oncology Inc | 2.2B | -31.2x | --- |
Celldex Therapeutics Inc | 2.2B | -11.4x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.9x | --- |
Agios Pharmaceuticals Inc | 2.1B | -7.3x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.42 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -11.3x |
Price/Sales (TTM) | 4,049.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.